This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
biotechnology: Archive
Bristol Myers (BMY) Announces Positive Updated NSCLC Data
by Zacks Equity Research
Bristol Myers' (BMY) repotrectinib shows durable efficacy benefits in patients with locally advanced or metastatic ROS1-Positive non-small cell lung cancer.
BMYPositive Net Change DVAXPositive Net Change SPRONo Net Change
biotechnology biotechs
Sonnet (SONN) Up as Ovarian Cancer Drug Enters Clinical Study
by Zacks Equity Research
Sonnet (SONN) receives FDA clearance to begin clinical development for its combination therapy of SON-1010 and Roche's atezolizumab, for the potential treatment of platinum-resistant ovarian cancer.
RHHBYPositive Net Change EBSNegative Net Change CORTPositive Net Change SONNPositive Net Change
biotechnology medical
Armata Pharmaceuticals, Inc. (ARMP) Now Trades Above Golden Cross: Time to Buy?
by Zacks Equity Research
When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?
ARMPNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Biotech Stock Roundup: GLTO Plunges on Setback, BLUE Offers Updates & More
by Zacks Equity Research
Regulatory updates from Galecto (GLTO) and Sonnet BioTherapeutics Holdings (SONN) are in focus in the biotech sector.
GILDPositive Net Change SONNPositive Net Change GLTONegative Net Change
biotechnology biotechs pharmaceuticals
Gilead (GILD), Tentarix To Develop Cancer, Inflammation Therapies
by Zacks Equity Research
Gilead (GILD) enters into a deal with Tentarix Biotherapeutics to discover and develop novel therapies for cancer and inflammation.
DVAXPositive Net Change GILDPositive Net Change SPRONo Net Change ACLXPositive Net Change
biotechnology biotechs pharmaceuticals
Galecto (GLTO) Down 71% as Lung Disease Candidate Fails
by Zacks Equity Research
Galecto's (GLTO) shares fall as the mid-stage study of GB0139 to treat idiopathic pulmonary fibrosis fails to meet its primary endpoint.
RHHBYPositive Net Change JAZZPositive Net Change CORTPositive Net Change GLTONegative Net Change
biotechnology medical
Novartis (NVS) Key Drugs and Pipeline Progress Fuel Growth
by Zacks Equity Research
Novartis (NVS) put up a strong performance year to date based on the solid performance of key drugs and encouraging pipeline progress.
NVSPositive Net Change RHHBYPositive Net Change BLCONegative Net Change
biotechnology pharmaceuticals
Apellis (APLS) Focuses on Empaveli to Fuel Its Growth
by Zacks Equity Research
Apellis' (APLS) first marketed product, Empaveli, continues to be the growth driver since its launch. However, Syfovre faces some safety concerns post promising takeoff.
AZNPositive Net Change ALNYPositive Net Change APLSPositive Net Change
biotechnology medical
Nektar (NKTR) Stock Surges 75% in a Week: Here's Why
by Zacks Equity Research
Nektar's (NKTR) shares rally almost 75% in a week on corrected efficacy data for rezpeg studies, earlier miscalculated by Eli Lilly.
LLYPositive Net Change JAZZPositive Net Change NKTRPositive Net Change CORTPositive Net Change
biotechnology medical
3 Biotech Stocks Poised to Beat Q2 Earnings Estimates
by Ekta Bagri
We look at a few biotech companies, LEGN, KOD, GRTX, which are poised to beat second-quarter earnings estimates.
GSKPositive Net Change KODPositive Net Change GRTXNegative Net Change LEGNPositive Net Change
biotechnology biotechs earnings pharmaceuticals
Immunovant (IMVT) Q1 Loss Wider Y/Y, Pipeline in Focus
by Zacks Equity Research
Immunovant's (IMVT) reports wider-than-expected loss for fiscal first-quarter 2023. IMVT is on track with the pipeline developments.
JAZZPositive Net Change CORTPositive Net Change ACADPositive Net Change IMVTPositive Net Change
biotechnology earnings medical
Biotech Stock Roundup: SAGE, GRTX Plunge on Setback, REGN to Buy DBTX & More News
by Zacks Equity Research
Regulatory updates from SAGE and Galera (GRTX) are in focus in the biotech sector.
REGNPositive Net Change VTGNPositive Net Change GRTXNegative Net Change
biotechnology pharmaceuticals
Regeneron (REGN) to Buy Decibel, Gains on Hearing Loss Therapies
by Zacks Equity Research
Regeneron (REGN) further builds upon its collaboration with Decibel by acquiring the company to expand its gene therapy programs for hearing loss.
REGNPositive Net Change SNYPositive Net Change
biotechnology pharmaceuticals
After Golden Cross, City Holding (CHCO)'s Technical Outlook is Bright
by Zacks Equity Research
Should investors be excited or worried when a stock's 50 -day simple moving average crosses above the 200-day simple moving average?
CHCOPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
After Golden Cross, FinWise Bancorp (FINW)'s Technical Outlook is Bright
by Zacks Equity Research
When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?
FINWPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Should You Buy Acadia Realty Trust (AKR) After Golden Cross?
by Zacks Equity Research
Is it a good or bad thing when a stock experiences a golden cross technical event?
AKRNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
First Bancorp (FBP)'s Technical Outlook is Bright After Key Golden Cross
by Zacks Equity Research
When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?
FBPPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Should You Buy Popular (BPOP) After Golden Cross?
by Zacks Equity Research
When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?
BPOPPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Top 5 Stocks Set to Beat on Earnings Next Week
by Nalak Das
We have narrowed our search to five stocks that are set to declare earnings results next week. These are: LEGN, TJX, WMT, ONON, BILL.
TJXPositive Net Change WMTNegative Net Change BILLNegative Net Change LEGNPositive Net Change ONONNegative Net Change
biotechnology consumer-discretionary internet retail
Deciphera (DCPH) Q2 Earnings Beat, Qinlock Drives Revenues
by Zacks Equity Research
Deciphera (DCPH) reports narrower-than-expected loss for the second quarter of 2023. Qinlock drives year-over-year sales.
PFENegative Net Change ADCTPositive Net Change IMGNPositive Net Change DCPHPositive Net Change
biotechnology earnings medical
FATE Q2 Earnings Beat on Lower Expenses, Revenues Miss
by Zacks Equity Research
FATE reports a lower-than-expected loss on a decline in operating expenses in the second quarter of 2023.
DVAXPositive Net Change FOLDPositive Net Change FATEPositive Net Change ACADPositive Net Change
biotechnology earnings pharmaceuticals
Emergent (EBS) Q2 Earnings Miss Estimates, Revenues Beat
by Zacks Equity Research
Emergent (EBS) reports wider-than-expected second-quarter loss. The company lowered its 2023 guidance for some products and services.
ADCTPositive Net Change IMGNPositive Net Change EBSNegative Net Change ACADPositive Net Change
biotechnology earnings medical
Amicus (FOLD) Misses on Q2 Earnings, Raises Revenue Guidance
by Zacks Equity Research
Amicus (FOLD) incurs wider-than-expected loss in the second quarter. Fabry disease drug Galafold reports encouraging revenues and the company raises its 2023 guidance for the same.
ADCTPositive Net Change IMGNPositive Net Change FOLDPositive Net Change ACADPositive Net Change
biotechnology earnings medical
Ironwood's (IRWD) Reports Q2 Loss, Linzess Volume Rises
by Zacks Equity Research
Ironwood (IRWD) reports loss for second-quarter 2023. The top line increases year over year, driven by growth in Linzess collaboration revenues.
AZNPositive Net Change IRWDNo Net Change ADCTPositive Net Change ABBVPositive Net Change
biotechnology earnings medical
Theravance's (TBPH) Q2 Earnings Beat Estimates, Revenues Miss
by Zacks Equity Research
Thervance's (TBPH) second-quarter 2023 loss is narrower than expected. Revenues rise year over year.
ADCTPositive Net Change IMGNPositive Net Change TBPHPositive Net Change VTRSNegative Net Change
biotechnology earnings medical